Aim To investigate predictive value of procalcitonin in diagnosis of sepsis in predicting positive blood culture, and possibility to predict final outcome in septic patients. Method This prospective study involved 106 hospitalized patients who met two or more criteria for systemic inflammatory response syndrome (SIRS). In comparison to Sepsis Related Organ Failure Assessment score (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II score procalcitonin (PCT), C-reactive protein and lactate levels were used to predict final outcome in septic patients (recorded as 28-day survival or non-survival). Using Receiver operating characteristic (ROC) curve the area under the curve (AUC) was calculated for diagnostic value and accuracy of different parameters with the best sensitivity and specificity for given cutoff values. Result Fifty-two out of 82 patients with documented sepsis had positive blood culture. Procalcitonin showed the best predictive value for both diagnosis of sepsis and bacteraemia with the cutoff value of 0.57 ng/mL (AUC 0.99) and 4.68 ng/mL (AUC 0.94), respectively. Serum lactate level showed the best 28-day mortality predictive value with the cutoff value of 3.25 mmol/L (AUC 0.95), and procalcitonin with the cutoff value of 15.05 ng/mL (AUC 0.92), followed by SOFA (AUC 0.92), CRP (AUC 0.84) and APACHE II score (AUC 0.83). Conclusion Monitoring of PCT in SIRS-positive patients raises possibility to distinguish between patients with sepsis and those with non-infectious SIRS. A significant correlation between PCT and SOFA, and APACHE II score in non-surviving septic patients indicates that PTC combined with clinical score could be useful for assessing severity of infection.
Dellinger R, Levy M, Carlet J, Bion J, Parker M, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intens Care Med. 2008. p. 17–60.
2.
Anonymous. Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. American College of Chest Physicians/ Society of Critical Care Medicine; 1992. p. 864–74.
3.
Peters R, Van Agtmael M, Danner S, Savelkoul P. Vandenbroucke-Grauls CM. New developments in the diagnosis of bloodstream infections. Lancet Infect Dis. 2004. p. 751–60.
4.
Mikić D. Relationship of concentrations of factor necrosis tumor alfa and interleukin 8 in blood with the severity and outcome of sepsis (master’s thesis) Beograd: Vojnomedicinska akademija. 2000.
5.
Müller B, Becker K, Schächinger H, Rickenbacher P, Huber P, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000. p. 977–83.
6.
Dandona P, Nix D, Wilson M, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994. p. 1605–8.
7.
Hohenberger P, Latz E, Kettelhack C, Rezai A, Schumann R, Schlag P. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-a and melphalan. Ann Surg Oncol. 2003. p. 562–8.
8.
Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clinica Chimica Acta. 2002. p. 17–29.
9.
Vincent J, Moreno R, Takala J, Willatts D, Mendonca D, Bruining A, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/ failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intens Care Med. 1996. p. 707–10.
10.
Knaus W, Draper E, Wagner D, Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med. 1985. p. 818–29.
11.
Levy M, Dellinger R, Townsend S, Linde-Zwirble W, Marshall J, Bion J, et al. Surviving Sepsis Campaign. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010. p. 367–74.
12.
Jaye D, Waites K. Clinical applications of C-reactive protein in paediatrics. Ped Infect Dis. 1997. p. 735–8.
13.
Hofer N, Muller Z, Resch W, B. An update on the use C-reactive protein in early-onset neonatal sepsis: current insights and new tasks. Neonatology. 2012. p. 25–36.
14.
Ugarte H, Silva E, Mercan D, Mendonca D, Vincent A, J-L. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1992. p. 498–504.
15.
Robriquet L, Sejourne C, Kipnis E, Dherbomez M, Fourrier F. A composite score combining procalcitonin, C-reactive protein and temperature has a high positive predictive value for the diagnosis of intensive care-acquired infections. BMC Infect Dis. 2013. p. 159.
16.
Lonxiang S, Bingchao H, Changting L, Zhaoxu L, Jie J, Peng D, et al. Value of soluble TREM-1, procalcitonin, and Creactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis. 2012. p. 157–9.
17.
Jaimes A, Rosa G, Valencia M, Arango C, Gomez C, Garcia A, et al. A latent class approach for sepsis diagnosis support use procalcitonin in the emergency room for diagnosis of severe sepsis. BMC Anesthesiol. 2013. p. 2247–53.
18.
Lee AJ, Kim SG. Mean cell volumes of neutrophils and monocytes are promising markers of sepsis in elderly patients. Blood Res. 2013. p. 193–7.
19.
Patil V, Morjaria J, Villers D, Babu F, S. Associations between procalcitonin and markers of bacterial sepsis. Medicine (Kaunas). 2012. p. 383–7.
20.
Huang W, Yin F, Shen D, Zhang Y, Luo Y, Liu C, et al. Predictive value of procalcitonin for excluding bloodstream infection: results of a retros-pective study and utility of a rapid, quantitative test for procalcitonin. J Int Med Res. 2013. p. 1671–8.
21.
Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohoun C. High serum procalcitonin concentration in patients with sepsis and infection. Lancet. 1993. p. 515–8.
22.
Crist-Crain M, Muller B. Procalcitonin in bacterial infections-hype, hope, more or less. Swiss Med Wkly. 2005. p. 451–60.
23.
Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012. p. 221–7.
24.
Tromp M, Lansdorp B, Bleeker-Rovers C, Gunnewiek J, Kullberg B, Pickkers P. Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. J Infect. 2012. p. 292–301.
25.
Kim M, Lim G, Kang S, Lee W, Suh J, Lee H. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011. p. 276–81.
26.
Charles P, Kus E, Aho S, Prin S, Doise J, Olsson N, et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis. 2009. p. 49–53.
27.
Yan S, Bin D, Ying-Chun X, Xi R, Wei D, Yao W. Early changes of procalcitonin predict bacteremia in patients with intensive care unit-acquired new fever. Chin Med J. 2013. p. 1832–7.
28.
Ephraim L, Brett J, Seth W, Raymond J, Jennifer C, Lawrence P, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med. 2012. p. 97–106.
29.
Al-Nawas B, Krammer I, Shah P. Procalcitonin in diagnosis of severe infections. Eur J Med Res. 1996. p. 331–3.
30.
Jensen J, Hein L, Lundgren B, Bestle M, Mohr T, Andersen M, et al. For the procalcitonin and survival study (PASS) group: procalcitonin-guided interventions against infections to increase appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011. p. 2048–58.
31.
Anand D, Das S, Ray S, Bhargava S, Srivastava L. Interrelationship between procalcitonin and organ failure in sepsis. Indian J Clin Biochem. 2014. p. 93–6.
32.
Zhang J, She D, Feng D, Jia Y, Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis. 2011. p. 53.
33.
Clec’h C, Ferriere F, Karoubi P, Fosse J, Cupa M, Hoang P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004. p. 1166–9.
34.
Becker K, Snider R, Nylen E. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Brit J Pharmacol. 2010. p. 253–64.
35.
Koliski A, Cat I, Giraldi D, Cat M. Blood lactate concentration as prognostic marker in critically ill children. J Pediatr (Rio J). 2005. p. 287–92.
36.
Shapiro N, Howell M, Talmor D, Nathanson L, Lisbon A, Wolfe R, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med. 2005. p. 524–8.
37.
Mikkelsen M, Miltiades A, Gaieski D, Goyal M, Fuchs B, Shah C, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009. p. 1670–7.
38.
Kim Y, Ha E, Jhag W, Park S. Early blood lactate area as a prognostic marker in paediatric septic shock. Intens Care Med. 2013. p. 1818–23.
39.
Chen Y, Li C. Arterial lactate improves the prognostic performance of severity score systems in septic patients in the ED. Am J Emerg Med. 2014. p. 6745–57.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
